Apatinib as second-line or later therapy in patients with advanced hepatocellular carcinoma (AHELP): a multicentre, double-blind, randomised, placebo-controlled, phase 3 trial

Qin, SK; Li, Q; Gu, SZ; Chen, XM; Lin, LZ; Wang, ZS; Xu, AB; Chen, X; Zhou, CC; Ren, ZG; Yang, L; Xu, L; Bai, YX; Chen, L; Li, J; Pan, HM; Cao, BW; Fang, WJ; Wu, W; Wang, G; Cheng, Y; Yu, Z; Zhu, X; Jiang, D; Lu, YY; Wang, HM; Xu, JM; Bai, L; Liu, YP; Lin, HL; Wu, CP; Zhang, Y; Yan, P; Jin, CL; Zou, JJ

Qin, SK (corresponding author), Nanjing Chinese Med Univ, Canc Ctr, Bayi Hosp, Nanjing 210002, Peoples R China.

LANCET GASTROENTEROLOGY & HEPATOLOGY, 2021; 6 (7): S59

Abstract

Background Inhibition of vascular endothelial growth factor receptor (VEGFR) has shown antitumour activity in advanced hepatocellular carcinoma, but f......

Full Text Link


Links

期刊讨论 | 中国SCI论文 | 期刊主页 | 投稿经验 | 杂志官网 | 投稿链接 | 作者需知 | PMC链接 | Pubmed全文检索